Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib

Core Insights - Nuvation Bio Inc. (NYSE:NUVB) is recognized as one of the top 14 booming stocks to buy currently, following its exclusive licensing agreement with Eisai Co. Ltd. to enhance the global reach of its lung cancer treatment pill, Taletrectinib [1][2]. Licensing Agreement - The exclusive licensing agreement allows Eisai to develop and commercialize Taletrectinib for advanced ROS1-positive non-small cell lung cancer (NSCLC) in Europe, the Middle East, North Africa, India, and other regions, while Nuvation retains full commercialization rights in the United States [2][3]. Financial Performance - For the fourth quarter of 2025, Nuvation reported net product revenue of $15.7 million for Taletrectinib, totaling $24.7 million since its launch in June of the previous year [4]. - Following the financial results, H.C. Wainwright adjusted its price target for Nuvation's stock from $18 to $17, while maintaining a Buy rating, noting that the quarterly revenue met expectations [4]. Analyst Ratings - Wall Street analysts have a consensus Strong Buy rating for Nuvation Bio, with an average price target of $11.38, indicating a potential upside of 76.16% as of January 12 [5].